Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Mol Pharm ; 18(8): 3116-3124, 2021 08 02.
Artículo en Inglés | MEDLINE | ID: mdl-34232660

RESUMEN

N-terminal glutamate can cyclize to form pyroglutamate (pGlu) in pharmaceutically relevant peptides and proteins. The reaction occurs nonenzymatically during storage for monoclonal antibodies and shows a strong 'pH' dependence in solution, but the solid-state reaction has not been studied in detail. This work investigates the effect of 'pH' and buffer species on pGlu formation for a model peptide (EVQLVESGGGLVQPGGSLR) in lyophilized solids and in solution. The model peptide was formulated from 'pH' 4 to 'pH' 9 in citrate, citrate-phosphate, phosphate, and carbonate buffers and stored at 50 °C for at least 10 weeks. pGlu formation and loss of the parent peptide were monitored by reversed-phase high-performance liquid chromatography. The apparent 'pH' dependence of the reaction rate in the solid state differed markedly from that in solution. Interestingly, in the 'pH' range often used to formulate mAbs ('pH' 5.5-6), the rate of pGlu formation in the solid state was greater than that in solution. The results have implications for the rational design of stable formulations of peptides and proteins, and for the transition from solid to solution formulations during development.


Asunto(s)
Concentración de Iones de Hidrógeno , Péptidos/química , Ácido Pirrolidona Carboxílico/química , Anticuerpos Monoclonales/química , Tampones (Química) , Catálisis , Química Farmacéutica/métodos , Cromatografía Líquida de Alta Presión/métodos , Cromatografía de Fase Inversa/métodos , Ciclización , Estabilidad de Medicamentos , Liofilización , Cinética , Estabilidad Proteica , Soluciones
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA